Case Study: Cipla Health’s Nicotex Nicotine patches launch in Indian Market

Cipla Health, an arm Cipla with a focus on consumer healthcare products, launched Nicotex Nicotine patches.

Nicotex Nicotine patch is a skin/transdermal patch that works on the proven principle of nicotine replacement therapy and helps in quit smoking in 12 weeks. Cipla is marketing Nicotex Gum and now launching line extension Nictotex Patch.

Cipla Health Limited is fourth largest Indian pharmaceutical company with net sales of Rs.14,280 crore.

Over 9 lakh die every year due to tobacco-related diseases in the country. One of the key challenges in this regard is the difficulty associated with quitting smoking.

The patch uses a step-down dosing therapy approach that will help smokers to keep their cravings and withdrawal symptoms in check, as reported by the company.

Nicotex Patch comes in 3 strengths; 21 mg, 14 mg and 7 mg. For those smoking more than 20 cigarettes, they need to start with the 21mg patch. For those smoking less than 20 cigarettes, they need to start with 14mg patch. The patch uses a step-down dosing therapy approach that will help smokers to keep their cravings and withdrawal symptoms in check.

The product will be available with leading chemists and key ecommerce partners across all major cities in India.

Nicotex Gum Commercial

Competitor Brand